MRNA Stock — Moderna Inc.

Moderna Inc. (MRNA)

MRNA is a low-cost Stock. Fund total return is 641.9% over the past 7.7 years, 413.7 points ahead of SPY at 228.2%.

Moderna is a biotechnology company developing messenger RNA medicines across multiple therapeutic areas, including respiratory vaccines (such as COVID-19 and RSV vaccines), latent virus vaccines, oncology treatments, and rare disease products, with collaborations spanning pharmaceutical companies, government agencies, and research institutions. The company does not currently distribute dividends. Moderna appeals primarily to growth-oriented investors seeking exposure to the biotechnology and vaccine development sectors rather than income investors.

MRNA performance versus SPY

Data as of August 28, 2026.

Fund total return is 641.9% over the past 7.7 years, 413.7 points ahead of SPY at 228.2%. Its deepest 1-year drawdown was 34.2%.

MRNA key facts

Data as of August 28, 2026.

Asset type

Stock

Asset class

Equity

Inception date

12/07/2018

Distribution frequency

None

Last close

$137.99

Market cap

$59,749,646,336

Average volume

25736829.0

Beta

0.899

Payout ratio

0.0

Forward P/E

23.0415

EPS

$-7.51

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. We show a 30-day SEC yield when the fund publishes one. Schwab and other issuers may report a TTM distribution yield or SEC yield on a different date — all can be valid; they are not interchangeable. Fund total return uses split-adjusted close with distributions reinvested from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is what the fund did, not your personal gain/loss. Figures below use Dividend Vision data as of August 28, 2026.

Distribution rate methodology · Distribution Safety Score methodology · SEC yield

Sources and review

Data as of August 28, 2026.

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MRNA risks and drawbacks

The deepest 1-year drawdown on record here is 34.2%.

Who may consider MRNA — and who may not

MRNA may suit someone looking for low-cost broad dividend exposure. It is a weaker fit for investors who need monthly cash flow (MRNA does not currently distribute); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

Compare MRNA

MRNA vs similar funds:

• MRNA vs MRNY

Frequently asked questions